Dexcom 10-Q 2024-09-30

Filed 2024-10-24. 1 sections, 207K characters. Original on sec.gov · Markdown · JSON

Full document

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File Number: 000-51222

dexcom-logo-green-rgb (1).jpg

DEXCOM, INC.

(Exact name of registrant as specified in its charter)

Delaware33-0857544
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
6340 Sequence Drive, San Diego**,** CA92121
(Address of principal executive offices)(Zip Code)

(858) 200-0200

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par Value Per ShareDXCMNasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 17, 2024, there were 390,595,390 shares of the registrant’s common stock outstanding.

Table of Contents

DexCom, Inc.
Table of Contents
Page
PART I. FINANCIAL INFORMATION
ITEM 1.Financial Statements
Consolidated Balance Sheets (unaudited) as of September 30, 2024 and December 31, 20234
Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2024 and 20235
Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended September 30, 2024 and 20236
Consolidated Statements of Stockholders’ Equity (unaudited) for the three and nine months ended September 30, 2024 and 20237
Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2024 and 20239
Notes to Consolidated Financial Statements (unaudited)10
ITEM 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations29
ITEM 3.Quantitative and Qualitative Disclosures about Market Risk42
ITEM 4.Controls and Procedures43
PART II. OTHER INFORMATION
ITEM 1.Legal Proceedings44
ITEM 1A.Risk Factors46
ITEM 2.Unregistered Sales of Equity Securities and Use of Proceeds46
ITEM 3.Defaults Upon Senior Securities46
ITEM 4.Mine Safety Disclosures46
[ITEM 5.](#i4d

Showing the first 8K of 207K characters. Open the full section